Ibrutinib Response in Cutaneous Transformed Lymphoplasmacytic Lymphoma

Lymphoplasmacytic lymphoma (LPL) accounts for approximately 2% of hematologic malignancies [1,2] and classically involves the bone marrow and peripheral blood, with less common involvement of the lymph nodes and spleen. LPL is often associated with a monoclonal paraprotein, usually IgM, which when symptomatic is referred to as theclinicalsyndromeWaldenströmmacroglobulinemia(WM).Disease manifestations may be due to the paraprotein or less commonly, secondary to tissue infiltration by lymphoma cells that consist of mature B-lymphocytes, plasmacytoid lymphocytes, and plasma cells. Cutaneous involvement is uncommon in LPL, most often related to the IgM and can range from dermatoses to crystal-storing histiocytosis cutaneous amyloidosis lymphoma cells is extremely rare, and when this occur, the neoplastic cells growth patterns interstitial, and dermal of cases of the differentiation